Effect of oral azithromycin three times per week on the reduction of asthma exacerbation in patients with persistent asthma

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

ISRCTN

Registry ID

ISRCTN14464685

Enrollment

160

Registered

2019-11-14

Start date

2018-06-01

Completion date

Unknown

Last updated

2022-08-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Persistent asthma Respiratory Asthma

Interventions

Eligible patients were allocated randomly into group A and in group B in equal number using block randomisation. Group A was treated with azithromycin 500 mg three times every alternate day for 24 wee

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Aged = 12 years 2. Persistent asthma patient

Exclusion criteria

Exclusion criteria: 1. Substantial parenchymal lung disease, such as emphysema 2. Current and ex-smokers 3. Patients with hearing impairment 4. Abnormally prolonged QTc interval 5. Asthma with bronchiectasis 6. Hypersensitivity to azithromycin

Design outcomes

Primary

Measure	Time frame
Number of asthma exacerbation episodes, measured by self-report at baseline and 24 weeks	—

Secondary

Measure	Time frame
At 24 weeks: 1. Total number of types of asthma exacerbation according to severity (moderate vs severe) 2. Adverse effects occurring in patients treated with azithromycin 3. Changes in self-reported asthma symptoms	—

Countries

Bangladesh

Contacts

Public ContactMohammad Ashik Imran Khan

ashikmrn@gmail.com+880 (0)2-55067131-40

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026